By preventing PP2A-B56α interaction with MYC, CIP2A gained scientific attention, and it is now considered a promising target for tumor treatment, particularly in AML [81,96,116], where it is overexpressed and promotes cell growth and neoplastic transformation [81]. This evidence concerns the gene MYC and acute myeloid leukemia.